Topical Timolol Gel for the Treatment of Infantile Hemangiomas

Exclusion Criteria

• •patients who are not otherwise generally healthy;
• •at risk for imminent ulceration, life-threatening, function-threatening, or ulcerated;
• •patients who have previously received systemic, intra-lesional or topical corticosteroids, imiquimod, vincristine, alpha-interferon, propranolol or other beta blockers;
• •patients who have previously been treated for his/her HOI, including any surgical and/or medical procedures;
• •patients whose mothers have been breastfeeding the patient while also being treated with beta-blockers, systemic corticosteroids, vincristine or alpha-interferon;
• •patients who have previously experienced any anaphylactic reactions; patients with an unclear diagnosis of HOI;
• •patients participating in another clinical study or living in the same household as an infant already participating in this study;
• •patients born prematurely who have not yet reached his/her term equivalent age; and patients with parent(s) or guardian(s) who cannot be contacted by telephone in case of emergency.